To Evaluate Pharmacokinetics and Safety of Two Different Formulation of Rebamipide in Healthy Volunteers

Inclusion criteria

• Subjects who give consent to voluntary participation by signing the informed consent form
• Healthy adult males aged ≥19 and ≤45 years at screening
• Subjects with weight ≥50 kg AND body mass index (BMI) ≥18.0 and ≤27.0

Exclusion criteria

• Subjects with hypersensitivity to the active ingredient of the IP or other anti-ulcer agents or history of clinically significant hypersensitivity
• Subjects with any past history of gastrointestinal diseases which can affect the absorption of the IP
• Subjects who have participated in other clinical trial and received any other investigational products within 3 months before the expected date of IP administration
• Subjects who have taken any inducers or inhibitors of drug metabolism enzyme
• Subjects who have been on diets that may affect the absorption, distribution, metabolism, and excretion of a drug
• Subjects who donated whole blood within 2 months or underwent apheresis within 1 month prior to obtaining informed consent or who did not agree to prohibit blood donation
• Smokers who have smoked >10 cigarettes per day within the last 6 months
• Subjects with any positive result on HBsAg, hepatitis C virus (HCV) Ab, HIV Ab, and venereal disease research laboratory (VDRL) tests